Search - tctmd.com

Displaying 201 - 220 of 567

Sort: Relevancy | Date

News Daily News

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Michael O'Riordan

May 04, 2020

News Features

Hopes High for Anti-inflammatories to Combat COVID-19 Immune System Storms

Caitlin E. Cox

April 23, 2020

News Conference News ACC 2020

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Todd Neale

April 02, 2020

News Conference News ACC 2020

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

Michael O'Riordan

April 02, 2020

Presentation ACC 2020

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Presenter: Deepak L. Bhatt

March 30, 2020

News Daily News

Better Adherence to Guideline Advice Pays Off After Acute MI

Yael L. Maxwell

March 11, 2020

News Daily News

Acute MI Symptom Clustering Differs in Men and Women: VIRGO

Michael O'Riordan

February 21, 2020

News Daily News

FDA Approves Two Generic Versions of Apixaban

Todd Neale

December 23, 2019

News Daily News

Aspirin Not Protective Against CVD in Black Patients

Caitlin E. Cox

December 18, 2019

News Daily News

FDA Approves Icosapent Ethyl for Reducing CVD Events

Michael O'Riordan

December 13, 2019

News Daily News

CV Risk Factors Largely Explain Sex Gap in NSTE ACS Outcomes: TIMI Trials

Caitlin E. Cox

December 11, 2019

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Todd Neale

December 10, 2019

News Daily News

Non-HDL Cholesterol Strongly Tied to Lifetime CVD Risk

Michael O'Riordan

December 03, 2019

News Conference News AHA 2019

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

Yael L. Maxwell

November 21, 2019

News Conference News AHA 2019

Lower Cholesterol Cuts CV Events: Treat Stroke to Target Trial

Shelley Wood

November 18, 2019

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

News Daily News

Dramatic Swings in Household Income Linked to CVD Risk: ARIC

Michael O'Riordan

October 09, 2019

Off Script: A (Not So) Brief History of Aspirin’s Rise and Fall

News Opinion Off Script TCT 2019

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Kwan S. Lee

September 29, 2019

News Conference News ESC 2019

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Yael L. Maxwell

September 10, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

Advertisement

Alirocumab ‘Modestly’ Cost-effective at Lower List Price: ODYSSEY OUTCOMES

Hopes High for Anti-inflammatories to Combat COVID-19 Immune System Storms

Icosapent Ethyl’s CV Benefit Closely Tied to Serum EPA Levels: REDUCE-IT

Pooled Inclisiran Data: Safe LDL-Lowering, Plus Hints of Fewer CVD Events

EPA Levels and Cardiovascular Outcomes in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial

Better Adherence to Guideline Advice Pays Off After Acute MI

Acute MI Symptom Clustering Differs in Men and Women: VIRGO

FDA Approves Two Generic Versions of Apixaban

Aspirin Not Protective Against CVD in Black Patients

FDA Approves Icosapent Ethyl for Reducing CVD Events

CV Risk Factors Largely Explain Sex Gap in NSTE ACS Outcomes: TIMI Trials

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

Non-HDL Cholesterol Strongly Tied to Lifetime CVD Risk

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

Lower Cholesterol Cuts CV Events: Treat Stroke to Target Trial

Recurrent Events Common Among Young Patients With CAD

Dramatic Swings in Household Income Linked to CVD Risk: ARIC

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content